Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis

Abstract

Objective We evaluated the utility of adhesion molecule (AM) and cytokine/chemokine expressions in blood and cerebrospinal fluid (CSF) as markers of disease activity in primary progressive multiple sclerosis (PPMS).

Methods The expressions of AMs and the levels of 17 cytokines in patients with PPMS (n = 25) were compared with those in secondary progressive MS (SPMS) (n = 18) and controls (n =11) and correlated with the volumes of focal and atrophic changes on MRI.

Results The expressions of very late activation antigen 4 (VLA-4), lymphocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1) in blood and CSF were higher in PPMS than in controls. Comparison between PPMS and SPMS showed higher levels of ICAM-1 in blood and CSF in PPMS, while the level of the vascular adhesion molecule (VCAM-1) was higher only in blood. There was no difference in the levels of cytokines in serum or CSF between PPMS and SPMS or controls, but evidence suggesting intrathecal synthesis of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) was found in PPMS. The expressions of CSF VLA-4 in PPMS correlated with the total volume of cerebral lesions and the number of diffuse brain lesions in MRI, while the amount of LFA-1 in CSF correlated with the number of spinal T2 lesions. The level of serum MIP-1β correlated with the T2 lesion load and EDSS score in PPMS.

Conclusions The upregulated expressions of AMs in blood and CSF and evidence for intrathecal synthesis of MCP-1 and IL-8 in PPMS indicate the importance of inflammatory changes in the pathogenesis of PPMS. Multiple Sclerosis 2007; 13: 701-707. http://msj.sagepub.com

Keywords

adhesion molecules blood CSF cytokines magnetic resonance imaging primary progressive multiple sclerosis secondary progressive multiple sclerosis

Get full access to this article

View all access options for this article.

References

Thompson AJ , Polman CH , Miller DH , McDonald WI , Brochet B. , Filippi Mmx et al. Primary progressive multiple sclerosis . Brain 1997; 120: 1085-96 .

Wolinsky JS The diagnosis ofl primary progressive multiple sclerosis . J Neurol Sci 2003; 206: 145-52 .

Bielekova B. , Martin R. Development ofl biomarkers in multiple sclerosis . Brain 2004; 127: 1463-78 .

Comabella M. , Pericot I. , Goertsches R. , Nos C. , Castillo M. , Blas Navarro J et al. Plasma osteopontin levels in multiple sclerosis . J Neuroimmunol 2005; 158: 231-39 .

Sastre-Garriga J. , Comabella M. , Brieva L. , Rovira A. , Tintore M. , Montalban X. Decreased MMP-9 production in primary progressive multiple sclerosis patients . Mult Scler 2004 ; 10: 376-80 .

Imitola J. , Chitnis T. , Khoury SJ Cytokines in multiple sclerosis: flrom bench to bedside . Pharmacol Ther 2005; 106: 163-77 .

Baraczka K. , Pozsonyi T. , Szongoth M. , Nekam K. , Megyeri A. , Balogh Z. et al. A study ofl increased levels ofl soluble vascular cell adhesion molecule-1 (sVCAM-1) in the cerebrospinal fluid ofl patients with multiple sclerosis and systemic lupus erythematosus . Acta Neurol Scand 1999; 99: 95-99 .

McDonnell GV , McMillan SA , Douglas JP , Droogan AG , Hawkins SA Raised CSF levels ofl soluble adhesion molecules across the clinical spectrum ofl multiple sclerosis . J Neuroimmunol 1998; 85: 186-92 .

Dore-Duffy P. , Newman W. , Balabanov R. , Lisak RP , Mainolfi E. , Rothlein R. et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum ofl patients with multiple sclerosis: correlation with clinical activity . Ann Neurol 1995; 37: 55-62 .

10.

Droogan AG , McMillan SA , Douglas JP , Hawkins SA Serum and cerebrospinal fluid levels ofl soluble adhesion molecules in multiple sclerosis: predominant intrathecal release ofl vascular cell adhesion molecule-1 . J Neuroimmunol 1996; 64: 185-91 .

11.

Kraus J. , Oschmann P. , Engelhardt B. , Schiel C. , Hornig C. , Bauer R. et al. Soluble and cell surflace ICAM-1 as markers flor disease activity in multiple sclerosis . Acta Neurol Scand 1998 ; 98: 102-109 .

12.

Sharief MK , Noori MA , Ciardi M. , Cirelli A. , Thompson EJ Increased levels ofl circulating ICAM-1 in serum and cerebrospinal fluid ofl patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage . J Neuroimmunol 1993; 43: 15-21 .

13.

Tsukada N. , Matsuda M. , Miyagi K. , Yanagisawa N. Increased levels ofl intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis flactor receptor in the cerebrospinal fluid ofl patients with multiple sclerosis . Neurology 1993; 43: 2679-82 .

14.

Bartosik-Psujek H. , Stelmasiak Z. The levels ofl chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity ofl the disease . Eur J Neurol 2005; 12: 49-54 .

15.

Beck J. , Rondot P. , Catinot L. , Falcoff E. , Kirchner H. , Wietzerbin J.

Increased production ofl interfleron gamma and tumor necrosis flactor precedes clinical maniflestation in multiple sclerosis: do cytokines trigger oflfl exacerbations?

Acta Neurol Scand 1988 ; 78: 318-23 .

16.

Duran I. , Martinez-Caceres EM , Rio J. , Barbera N. , Marzo ME , Montalban X. Immunological profile ofl patients with primary progressive multiple sclerosis. Expression ofl adhesion molecules . Brain 1999 ; 122: 2297-307 .

17.

Elovaara I. , Ukkonen M. , Leppakynnas M. , Lehtimaki T. , Luomala M. , Peltola J. et al. Adhesion molecules in multiple sclerosis: relation to subtypes ofl disease and methylprednisolone therapy . Arch Neurol 2000; 57: 546-51 .

18.

Eikelenboom MJ , Killestein J. , Izeboud T. , Kalkers NF , Baars PA , van Lier RA et al. Expression ofl adhesion molecules on peripheral lymphocytes predicts fluture lesion development in MS . J Neuroimmunol 2005; 158: 222-30 .

19.

Calabresi PA , Pelfrey CM , Tranquill LR , Maloni H. , McFarland HF VLA-4 expression on peripheral blood lymphocytes is downregulated aflter treatment ofl multiple sclerosis with interfleron beta . Neurology 1997; 49: 1111-16 .

20.

Giovannoni G. , Lai M. , Thorpe J. , Kidd D. , Chamoun V. , Thompson AJ et al. Longitudinal study ofl soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging . Neurology 1997; 48: 1557-65 .

21.

Hartung HP , Reiners K. , Archelos JJ , Michels M. , Seeldrayers P. , Heidenreich F. et al. Circulating adhesion molecules and tumor necrosis flactor receptor in multiple sclerosis: correlation with magnetic resonance imaging . Ann Neurol 1995; 38: 186-93 .

22.

Khoury SJ , Orav EJ , Guttmann CR , Kikinis R. , Jolesz FA , Weiner HL Changes in serum levels ofl ICAM and TNF-R correlate with disease activity in multiple sclerosis . Neurology 1999; 53: 758-64 .

23.

Rieckmann P. , Martin S. , Weichselbraun I. , Albrecht M. , Kitze B. , Weber T. et al. Serial analysis ofl circulating adhesion molecules and TNF receptor in serum flrom patients with multiple sclerosis: cICAM-1 is an indicator flor relapse . Neurology 1994; 44: 2367-72 .

24.

Rieckmann P. , Altenhofen B. , Riegel A. , Baudewig J. , Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis . Ann Neurol 1997; 41: 326-33 .

25.

Rieckmann P. , Altenhofen B. , Riegel A. , Kallmann B. , Felgenhauer K. Correlation ofl soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis . Mult Scler 1998; 4: 178-82 .

26.

Elovaara I. , Lalla M. , Spare E. , Lehtimaki T. , Dastidar P. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS . Neurology 1998; 51: 1703-708 .

27.

Kraus J. , Engelhardt B. , Chatzimanolis N. , Bauer R. , Tofighi J. , Kuehne BS et al. Cell surflace bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures ofl subclinical disease severity and activity . J Neuroimmunol 2002; 122: 175-85 .

28.

Lublin FD , Reingold SC Defining the clinical course ofl multiple sclerosis: results ofl an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials ofl New Agents in Multiple Sclerosis . Neurology 1996; 46: 907-11 .

29.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD et al. Recommended diagnostic criteria flor multiple sclerosis: guidelines flrom the International Panel on the diagnosis ofl multiple sclerosis . Ann Neurol 2001; 50: 121-27 .

30.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-52 .

31.

Heinonen T. , Dastidar P. , Eskola H. , Frey H. , Ryymin P. , Laasonen E. Applicability ofl semi-automatic segmentation flor volumetric analysis ofl brain lesions . J Med Eng Technol 1998; 22: 173-78 .

32.

Heinonen T. , Dastidar P. , Kauppinen P. , Malmivuo J. , Eskola H. Semi-automatic tool flor segmentation and volumetric analysis ofl medical images . Med Biol Eng Comput 1998; 36: 291-96 .

33.

Ukkonen M. , Dastidar P. , Heinonen T. , Laasonen E. , Elovaara I. Volumetric quantitation by MRI in primary progressive multiple sclerosis: volumes ofl plaques and atrophy correlated with neurological disability . Eur J Neurol 2003; 10: 663-69 .

34.

Dastidar P. , Heinonen T. , Lehtimaki T. , Ukkonen M. , Peltola J. , Erila T. et al. Volumes ofl brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis . J Neurol Sci 1999; 165: 36-42 .

35.

Lycklama á Nijeholt GJ , van Walderveen MA , Castelijns JA , van Waesberghe JH , Polman C. , Scheltens P. et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms . Brain 1998; 121: 687-97 .

36.

Dupont NC , Wang K. , Wadhwa PD , Culhane JF , Nelson EL Validation and comparison ofl luminex multiplex cytokine analysis kits with ELISA: Determinations ofl a panel ofl nine cytokines in clinical sample culture supernatants . J Reprod Immunol 2005; 66: 175-91 .

37.

Revesz T. , Kidd D. , Thompson AJ , Barnard RO , McDonald WI A comparison ofl the pathology ofl primary and secondary progressive multiple sclerosis . Brain 1994; 117: 759-65 .

38.

Thompson AJ , Kermode AG , MacManus DG , Kendall BE , Kingsley DP , Moseley IF et al. Patterns ofl disease activity in multiple sclerosis: clinical and magnetic resonance imaging study . BMJ 1990; 300: 631-34 .

39.

Thompson AJ , Kermode AG , Wicks D. , MacManus DG , Kendall BE , Kingsley DP et al. Major diflflerences in the dynamics ofl primary and secondary progressive multiple sclerosis . Ann Neurol 1991; 29: 53-62 .

40.

Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system . Cell 1996; 85: 299-302 .

41.

Sastre-Garriga J. , Ingle G. , Chard D. , Ramió-Torrentà L. , Miller D. , Thompson A. Grey and white matter atrophy in early clinical stages ofl primary progressive multiple sclerosis . NeuroImage 2004; 22: 353-59 .

42.

Lund BT , Ashikian N. , Ta HQ , Chakryan Y. , Manoukian K. , Groshen S. et al. Increased CXCL8 (IL-8) expression in multiple sclerosis . J Neuroimmunol 2004; 155: 161-71 .

43.

Maurer M. , von Stebut E. Macrophage inflammatory protein-1 . Int J Biochem Cell Biol 2004; 36: 1882-86 .